Big Year Ahead, page-128

Hi H28. Would key price considerations be along the lines of, potential sales/ Maker need, term of IP, how novel the treatment is, if there is potential for big Pharma share of wallet pressures leading to a bidding war. Many variables there.
If 321 & or 761 become part of standard of care or standard of care on their own. The potential could be 10s of billions. Long way from it yet, but the data to date hasn’t ruled out the possibility. We remain in the game with the luxury of thinking big until proven otherwise. Imm just enjoying the ride in the knowledge that people with serious illness will be the beneficiary’s of any IMM success. With that, so too for holders financially. Emotionally involved, unashamedly yes. Prepared for failure, yes. Nothing happened to those that didn’t try. Let’s roll.